[Tubulointerstitial nephritis: Pathogenesis, pathophysiology, and therapy].
Maruyama
Shoichi
S
Field of Clinical Immunology, Department of Internal Medicine, Nagoya University Graduate School of Medicine.
Matsuo
Seiichi
S
D000900:Anti-Bacterial Agents / Q000009:adverse effects; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D015551:Autoimmunity; D001424:Bacterial Infections; D018932:Chemokine CCL2 / Q000502:physiology; D006801:Humans; D008712:Methicillin / Q000009:adverse effects; D009395:Nephritis, Interstitial / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D009569:Nitric Oxide / Q000502:physiology; D012084:Renin-Angiotensin System / Q000502:physiology; D014777:Virus Diseases / Q000150:complications
D000900:Anti-Bacterial Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; C111835:CCL2 protein, human; D018932:Chemokine CCL2; D009569:Nitric Oxide; D008712:Methicillin